(NASDAQ: INCY) Incyte's forecast annual revenue growth rate of 7.91% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.9%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.24%.
Incyte's revenue in 2024 is $4,075,860,000.On average, 10 Wall Street analysts forecast INCY's revenue for 2024 to be $810,327,211,196, with the lowest INCY revenue forecast at $793,351,063,904, and the highest INCY revenue forecast at $820,081,285,953. On average, 10 Wall Street analysts forecast INCY's revenue for 2025 to be $893,307,645,598, with the lowest INCY revenue forecast at $857,123,305,230, and the highest INCY revenue forecast at $943,005,630,333.
In 2026, INCY is forecast to generate $988,731,552,233 in revenue, with the lowest revenue forecast at $916,671,497,196 and the highest revenue forecast at $1,073,077,298,950.